# Opdivo Qvantig (hyaluronidase-nvhy; nivolumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/hyaluronidase-nvhy-nivolumab

> The FDA approved Opdivo Qvantig (hyaluronidase-nvhy; nivolumab), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on December 27, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Opdivo Qvantig (hyaluronidase-nvhy; nivolumab) |
| Codes |  |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications |  |
| Modality | biologic |
| FDA designations | none disclosed |

## Timeline

### December 27, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761381 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20241227, review_priority STANDARD; sponsor_name BRISTOL-MYERS SQUIBB; product OPDIVO QVANTIG (HYALURONIDASE-NVHY; NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761381%22
- openFDA Drugs@FDA: "BLA761429 ORIG-1 (Type 9 - New indication submitted as distinct BLA, consolidated): submission_status AP, submission_status_date 20241227, review_priority STANDARD; sponsor_name BRISTOL-MYERS SQUIBB; product OPDIVO QVANTIG (HYALURONIDASE-NVHY; NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761429%22

### October 27, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761381 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20251027, review_priority STANDARD; sponsor_name BRISTOL-MYERS SQUIBB; product OPDIVO QVANTIG (HYALURONIDASE-NVHY; NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761381%22
- openFDA Drugs@FDA: "BLA761381 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20251027, review_priority STANDARD; sponsor_name BRISTOL-MYERS SQUIBB; product OPDIVO QVANTIG (HYALURONIDASE-NVHY; NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761381%22

### November 24, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761381 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20251124, review_priority STANDARD; sponsor_name BRISTOL-MYERS SQUIBB; product OPDIVO QVANTIG (HYALURONIDASE-NVHY; NIVOLUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761381%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/hyaluronidase-nvhy-nivolumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Opdivo Qvantig (hyaluronidase-nvhy; nivolumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/hyaluronidase-nvhy-nivolumab

```bibtex
@misc{secapidev_pdufa_hyaluronidase_nvhy_nivolumab_20261116,
  title        = {Opdivo Qvantig (hyaluronidase-nvhy; nivolumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/hyaluronidase-nvhy-nivolumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_hyaluronidase_nvhy_nivolumab_20261116","title":"Opdivo Qvantig (hyaluronidase-nvhy; nivolumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/hyaluronidase-nvhy-nivolumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
